STAAR Visian Toric ICL Post-Approval Study (TICL-PAS)

March 12, 2026 updated by: Staar Surgical Company

Post-Approval Study of the Visian Toric Implantable Collamer Lens

The objective of this study is to evaluate the long term (i.e. 24 months) clinical performance of the Visian® Toric Implantable Collamer® Lens (ICL).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be conducted at 6-8 clinical sites in the US, by surgeons qualified by experience and training to implant Visian Toric ICLs.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
125

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Hawaii
      • Honolulu, Hawaii, United States, 96814
        • Aloha Laser Vision, LLC
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Price Vision Group,
    • Maryland
      • Bowie, Maryland, United States, 20716
        • Solomon Eye Physicians and Surgeons/Bowie Vision Institute
    • Nebraska
      • Omaha, Nebraska, United States, 68137
        • Vance Thompson Vision
    • North Dakota
      • West Fargo, North Dakota, United States, 58078
        • Vance Thompson Vision
    • Ohio
      • Brecksville, Ohio, United States, 44141
        • Cleveland Eye Clinic
    • Texas
      • Dallas, Texas, United States, 75243
        • Key-Whitman Eye Center
    • Utah
      • Draper, Utah, United States, 84020
        • Hoopes Vision/Hoopes, Durrie, Rivera Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

21 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Moderate to high myopia with astigmatism correctable with available TICL powers.
  • Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE) for 1 year prior to implantation.
  • Able and willing to return for scheduled follow-up examinations after surgery.
  • Able to read, understand and provide written informed consent on the Institutional Review Board (IRB)-approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

  • Insulin-dependent diabetes or diabetic retinopathy.
  • History of previous ocular surgery.
  • Cataract of any grade.
  • Monocular.
  • Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study.
  • Other protocol-specified exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Visian TICL
STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
Device: Visian TICL
The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Other Names:
  • Visian Toric ICL
  • TMICL

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Axis Orientation of the TICL
Time Frame: 18 to 24 months postoperative
Rotation of the TICL of less than or equal to five degrees in 90% of treated eyes between 18 and 24 months postoperative
18 to 24 months postoperative

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Absolute Rotation of the TICL Between Visits (Change From Operative Visit to Day 1)
Time Frame: Day 1 (1-2 days postoperatively)
Absolute Rotation of the TICL in treated eyes between visits (change from Operative visit to Day 1)
Day 1 (1-2 days postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Day 1 to Week 1)
Time Frame: Week 1 (5-9 days postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Day 1 to Week 1)
Week 1 (5-9 days postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Week 1 to Month 1)
Time Frame: Month 1 (3-5 weeks postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Week 1 to Month 1)
Month 1 (3-5 weeks postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Month 1 to Month 3)
Time Frame: Month 3 (10-14 weeks postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Month 1 to Month 3)
Month 3 (10-14 weeks postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Month 3 to Month 6)
Time Frame: Month 6 (21 - 26 weeks postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Month 3 to Month 6)
Month 6 (21 - 26 weeks postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Month 6 to Month 12)
Time Frame: Month 12 (11 - 14 months postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Month 6 to Month 12)
Month 12 (11 - 14 months postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Month 12 to Month 18)
Time Frame: Month 18 (17 - 21 months postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Month 12 to Month 18)
Month 18 (17 - 21 months postoperatively)
Absolute Rotation of the TICL Between Visits (Change From Month 18 to Month 24)
Time Frame: Month 24 (23 - 27 months postoperatively)
Absolute rotation of the TICL in treated eyes between visits (Change from Month 18 to Month 24)
Month 24 (23 - 27 months postoperatively)
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Operative Visit)
Time Frame: Operative Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Operative Visit
Absolute Rotation of the TICL <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Day 1)
Time Frame: Day 1 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Day 1 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Week 1 Visit)
Time Frame: Week 1 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Week 1 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 1 Visit)
Time Frame: Month 1 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 1 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 3 Visit)
Time Frame: Month 3 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 3 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 6 Visit)
Time Frame: Month 6 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 6 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 12 Visit)
Time Frame: Month 12 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 12 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 18 Visit)
Time Frame: Month 18 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 18 Visit
Absolute Rotation <5 Degrees, <10 Degrees, <20 Degrees, and <30 Degrees From the Intended Orientation at Each Visit (Month 24 Visit)
Time Frame: Month 24 Visit
Absolute rotation of the TICL in treated eyes <5 degrees, <10 degrees, <20 degrees, and <30 degrees from the intended orientation at each visit
Month 24 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Operative Visit)
Time Frame: Operative Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Operative Visit)
Operative Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Day 1 Visit)
Time Frame: Day 1 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Day 1 Visit)
Day 1 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Week 1 Visit)
Time Frame: Week 1 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Week 1 Visit)
Week 1 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month 1 Visit)
Time Frame: Month 1 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 1 Visit)
Month 1 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month 3 Visit)
Time Frame: Month 3 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 3 Visit)
Month 3 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month 6 Visit)
Time Frame: Month 6 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 6 Visit)
Month 6 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month12 Visit)
Time Frame: Month 12 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 12 Visit)
Month 12 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month 18 Visit)
Time Frame: Month 18 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 18 Visit)
Month 18 Visit
Absolute Rotation of the TICL From the Intended Orientation at Each Visit (Month 24 Visit)
Time Frame: Month 24 Visit
Absolute Rotation of the TICL in treated eyes from the intended orientation at each visit (Month 24 Visit)
Month 24 Visit
Manifest Refraction Spherical Equivalent (MRSE) at Month 1
Time Frame: Month 1
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 1
Manifest Refraction Spherical Equivalent (MRSE) at Month 3
Time Frame: Month 3
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 3
Manifest Refraction Spherical Equivalent (MRSE) at Month 6
Time Frame: Month 6
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 6
Manifest Refraction Spherical Equivalent (MRSE) at Month 12
Time Frame: Month 12
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 12
Manifest Refraction Spherical Equivalent (MRSE) at Month 18
Time Frame: Month 18
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 18
Manifest Refraction Spherical Equivalent (MRSE) at Month 24
Time Frame: Month 24
Postoperative manifest refraction spherical equivalent (MRSE) at each visit
Month 24
Manifest Refraction Cylinder at Month 1
Time Frame: Month 1
Postoperative manifest refraction cylinder at each visit
Month 1
Manifest Refraction Cylinder at Month 3
Time Frame: Month 3
Postoperative manifest refraction cylinder at each visit
Month 3
Manifest Refraction Cylinder at Month 6
Time Frame: Month 6
Postoperative manifest refraction cylinder at each visit
Month 6
Manifest Refraction Cylinder at Month 12
Time Frame: Month 12
Postoperative manifest refraction cylinder at each visit
Month 12
Manifest Refraction Cylinder at Month 18
Time Frame: Month 18
Postoperative manifest refraction cylinder at each visit
Month 18
Manifest Refraction Cylinder at Month 24
Time Frame: Month 24
Postoperative manifest refraction cylinder at each visit
Month 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Staar Surgical Company

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Joanne Egamino, PhD, VP, Clinical Affairs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 21, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 11, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 11, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 10, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 13, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 18, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CP18-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myopic Astigmatism

Clinical Trials on Visian TICL

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings